<strong>Progress of Voltage Gated Sodium Channel Nav1.7 and its Specific Blockers in Nneuropathic pain</strong>

Abstract

Abstract:Voltage gated sodium channels (Nav) play important roles in generation and conduction of pain. In pain conduction pathway, Nav1.7 is selectively expressed in small-diameter peripheral somatic sensory neurons and sympathetic ganglion neurons. Nav1.7 modulates neuronal excitability through amplifing subthreshold of depolarizations and setting up the thresholds of Nav1.8 and Nav1.9. This review will focus on the progress of neuropathic pain caused by mutations in Nav1.7. Nav1.7 can be used as an effective target for the treatment of pain. Highly selective Nav1.7 blockers will be of great clinical value in the treatment of pain.

Key words:neuropathic pain,voltage gated sodium channel,Nav1.7,sodium channel blocker,dorsal root ganglia,channel structure

WANG Chuan，SHAN Bin，WANG Qiong，ZHANG Hai-lin.Progress of Voltage Gated Sodium Channel Nav1.7 and its Specific Blockers in Nneuropathic pain[J]. Acta Neuropharmacologica, 2015, 5(5): 49-56.

References

[1] Jonathan W Theile, Theodore R Cummins. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes [J]. Frontiers in pharmacology, 2011, 2: 54.

[2] Anthony M Rush, Theodore R Cummins, Stephen G Waxman. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons [J]. J Physiology, 2007, 579(1): 1-14.

[3] Sulayman D Dib-Hajj, Yang Yang, Joel A Black, et al. The NaV1. 7 sodium channel: from molecule to man [J]. Nature Reviews Neuroscience, 2013, 14(1): 49-62.

[4] Habib A M, Wood J N, Cox J J. Sodium channels and pain[M]//Pain Control, Springer Berlin Heidelberg, 2015: 39-56.

[5] Habib A M, Wood J N, Cox J J. Sodium channels and pain[M]//Pain Control, Springer Berlin Heidelberg, 2015: 39-56.

[6] Janneke G J Hoeijmakers, Catharina G Faber, Ingemar S J Merkies, et al. Painful peripheral neuropathy and sodium channel mutations[J]. Neuroscience letters, 2015, 596: 51-59.

[7] Michael S Minett, Sarah Falk, Sonia Santana-Varela, et al. Pain without nociceptors? Nav1. 7-independent pain mechanisms[J]. Cell Reports, 2014, 6(2): 301-312.

[8] Michael F Mulroy. Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures [J]. Regional Anesthesia and Pain Medicine, 2002, 27(6): 556-561.

[9] Glenn F King, Irina Vetter. No gain, no pain: NaV1. 7 as an analgesic target[J]. ACS Chemical Neuroscience, 2014, 5(9): 749-751.

[10] Edward C Emery, Ana Paula Luiz, John N Wood. NaV1. 7 and other voltage-gated sodium channels as drug targets for pain relief[J]. Expert Opinion on Therapeutic Targets, 2016 (just-accepted).

[11] David E Clapham, David Julius, Craig Montell, et al. International union of pharmacology. XLIX. nomenclature and structure-function relationships of transient receptor potential channels [J]. Pharmacological Reviews, 2005, 57(4): 427-450.

[12] William A Catterall. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels [J]. Neuron, 2000, 26(1): 13-25.

[13] William J Brammar. Ion channel factsbook: voltage-gated channels[B]. Academic Press, 1998.

[14] Frank H Yu, William A Catterall. Overview of the voltage-gated sodium channel family [J]. Genome Biol, 2003, 4(207): 10.1186.

[15] Jian Payandeh, Todd Scheuer, Zheng Ning, et al. The crystal structure of a voltage-gated sodium channel [J]. Nature, 2011, 475(7356): 353-358.

[16] Sulayman D Dib-Hajj, Theodore R Cummins, Joel A Black, et al. Sodium channels in normal and pathological pain [J]. Annual Review Neuroscience, 2010, 33: 325-347.

[17] Laiche Djouhri, Richard Newton, Simon Rock Levinson, et al. Sensory and electrophysiological properties of guinea pig sensory neurones expressing Nav1.7 (PN1) Na+ channel α subunit protein [J]. J Physiology, 2003, 546(2): 565-576.

[18] Joost P H Drenth, Stephen G Waxman. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders [J]. J Clinical Investigation, 2007, 117(12): 3603-3609.

[19] David L H Bennett, C Geoffrey Woods. Painful and painless channelopathies[J]. The Lancet Neurology, 2014, 13(6): 587-599.

[20] Joost P H Drenth, Jan J Michiels. Erythromelalgia and erythermalgia: diagnostic differentiation [J]. J International Dermatology, 1994, 33(6): 393-397.

[21] Finley W H, Lindsey J R, Fine J D, et al. Autosomal dominant erythromelalgia [J]. J American Medical Genetics, 1992, 42(3): 310-315.

[22] Jan Jacques Michiels, Joost P H Drenth, Perry J J GENDEREN. Classification and diagnosis of erythromelalgia and erythermalgia [J]. J International Dermatology, 1995, 34(2): 97-100.

[23] 杨晨颖, 王克威. 电压门控钠通道 NaV1. 7 与痛信号的产生[J]. 生理科学进展, 2007, 38(4): 351-354.

[24] Michiels J J, Drenth J P H, Genderen P J J. Classification and diagnosis of erythromelalgia and erythermalgia [J]. International journal of dermatology, 1995, 34(2): 97-100.

[25] Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia [J]. J Medical Genetics, 2004, 41(3): 171-174.

[26] Han C, Rush A M, Dib‐Hajj S D, et al. Sporadic onset of erythermalgia: A gain‐of‐function mutation in Nav1. 7 [J]. Annals of Neurology, 2006, 59(3): 553-558.

[27] Asheebo Rojas, Wu Jian-ping, Wang Run-ping, et al. Gating of the ATP-sensitive K+ channel by a pore-lining phenylalanine residue [J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2007, 1768(1): 39-51.

[28] Patrick L Sheets, James O Jackson, Stephen G Waxman, et al. A Nav1. 7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity [J]. J Physiology, 2007, 581(3): 1019-1031.

[29] Lampert A, Eberhardt M, Waxman S G. Altered sodium channel gating as molecular basis for pain: contribution of activation, inactivation, and resurgent currents[M]//Voltage Gated Sodium Channels. Springer Berlin Heidelberg, 2014: 91-110.

[30] Lampert A, Eberhardt M, Waxman S G. Altered sodium channel gating as molecular basis for pain: contribution of activation, inactivation, and resurgent currents[M]//Voltage Gated Sodium Channels. Springer Berlin Heidelberg, 2014: 91-110.

[31] Anthony M Rush, Sulayman D Dib-Hajj, Liu Shu-jun, et al. A single sodium channel mutation produces hyper-or hypoexcitability in different types of neurons [J]. Proceedings of the National Academy of Sciences, 2006, 103(21): 8245-8250.

[32] Juan J Toledo-Aral, Brenda L Moss, He Zhi-jun, et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons [J]. Proceedings of the National Academy of Sciences, 1997, 94(4): 1527-1532.

[33] Janneke G J Hoeijmakers, Han Chong-yang, Ingemar S J Merkies, et al. Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation [J]. Brain, 2012, 135(2): 345-358.

[34] Theodore R Cummins, Sulayman D Dib-Hajj, Stephen G Waxman. Electrophysiological properties of mutant Nav1. 7 sodium channels in a painful inherited neuropathy [J]. J Neuroscience, 2004, 24(38): 8232-8236.

[35] 渠兴乾, 程志军, 沈伯雄. 电压门控型钠离子通道 Nav1. 7 的研究进展[J]. 四川医学, 2009, 30(4): 597-599.

[36] Estacion M, Dib-Hajj S D, Benke P J, et al. NaV1. 7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders [J]. J Neuroscience, 2008, 28(43): 11079-11088.

[37] Cheng Xiao-yang, Sulayman D Dib-Hajj, Lynda Tyrrell, et al. Research Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders [J]. Mol Pain, 2010, 6(24): 1-12.

[38] Brian W Jarecki, Andrew D Piekarz, James O Jackson. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents [J]. J Clinical Investigation, 2010, 120(1): 369.

[39] Goldberg Y P, MacFarlane J, MacDonald M L, et al. Loss‐of‐function mutations in the Nav1. 7 gene underlie congenital indifference to pain in multiple human populations [J]. Clinical Genetics, 2007, 71(4): 311-319.

[40] Jan Weiss, Martina Pyrski, Eric Jacobi, et al. Loss-of-function mutations in sodium channel Nav1. 7 cause anosmia[J]. Nature, 2011, 472(7342): 186-190.

[41] James J Cox, Frank Reimann, Adeline K Nicholas, et al. An SCN9A channelopathy causes congenital inability to experience pain [J]. Nature, 2006, 444(7121): 894-898.

[42] Roland Staudl, Donald D Pricel, David M Janickel, et al. Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain [J]. European J Pain, 2011, 15(3): 223-230.

[43] Joel A Black, Liu Shu-jun, Masaki Tanaka, et al. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain [J]. Pain, 2004, 108(3): 237-247.

[44] Harry J Gould, John D England, R Denis Soignier, et al. Ibuprofen blocks changes in NaV1.7 and 1.8 sodium channels associated with complete freund’s adjuvant-induced inflammation in rat [J]. J Pain, 2004, 5(3): 270–280.

[45] Munmun Chattopadhyay, Marina Mata, David J Fink. Continuous δ-opioid receptor activation reduces neuronal voltage-gated sodium channel (Nav1.7) levels through activation of protein kinase C in painful diabetic neuropathy [J]. J Neuroscience, 2008, 28(26): 6652-6658.

[46] Munmun Chattopadhyay, Zhou Zhi-gang, Hao Shuang-lin, et al. Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy [J]. Mol Pain, 2012, 8(1): 17.

[47] David C Yeomans, Simon Rock Levinson, Peters M C, et al. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents [J]. Human Gene Therapy, 2005, 16(2): 271-277.

[48] Mark Estacion, T Patrick Harty, Jin-Sung Choi, et al. A sodium channel gene SCN9A polymorphism that increases nociceptor excitability [J]. Annals of Neurology, 2009, 66(6): 862-866.

[49] Frank Reimann, James J Cox, Inna Belfer, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A [J]. Proceedings of the National Academy of Sciences, 2010, 107(11): 5148-5153.

[50] Andrew S C Rice, Raymond G Hill. New treatments for neuropathic pain [J]. Annu Rev Med, 2006, 57: 535-551.

[51] Caroline R Fertleman, Mark D Baker, Keith A Parker, et al. SCN9AMutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes [J]. Neuron, 2006, 52(5): 767-774.

[52] Jin-Sung Choi, Zhang Li-li, Sulayman D Dib-Hajj, et al. Mexiletine-responsive erythromelalgia due to a new Nav1.7 mutation showing use-dependent current fall-off [J]. Experimental Neurology, 2009, 216(2): 383-389.

[53] Tanya Z Fischer, Elaine S Gilmore, Mark Estacion, et al. A novel Nav1.7 mutation producing carbamazepine‐responsive erythromelalgia [J]. Annals of Neurology, 2009, 65(6): 733-741.

[54] Sriram Tyagarajan, Prasun K Chakravarty, Zhou Bi-shan, et al. Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain [J]. Bioorganic & Medicinal Chemistry Letters, 2010, 20(24): 7479-7482.

[55] Clare London, Scott B Hoyt, William H Parsons, et al. Imidazopyridines: A novel class of hNa1.7 channel blockers [J]. Bioorganic & Medicinal Chemistry Letters, 2008, 18(5): 1696-1701.

[56] Sultan Chowdhury, Mikhail Chafeev, Shifeng Liu, et al. Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain [J]. Bioorganic & Medicinal Chemistry Letters, 2011, 21: 3676–3681.

[57] Scott B Hoyt, Clare London, David Gorin, et al. Discovery of a novel class of benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain [J]. Bioorganic & Medicinal Chemistry Letters, 2007, 17(16): 4630-4634.

[58] Middleton R E, Warren V A, Kraus R L, et al. Two tarantula peptides inhibit activation of multiple sodium channels [J]. Biochemistry, 2002, 41(50): 14734-14747.

[59] William A Schmalhofer, Jeff Calhoun, Rachel Burrows, et al. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors [J]. Molecular Pharmacology, 2008, 74(5): 1476-1484.

[60] Drew C Tilley, Kenneth S Eum, Sebastian Fletcher-Taylor, et al. Chemoselective tarantula toxins report voltage activation of wild-type ion channels in live cells[J]. Proceedings of the National Academy of Sciences, 2014, 111(44): E4789-E4796.

[61] Xiao Yu-cheng, Kenneth Blumenthal, James O Jackson, et al. The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation [J]. Molecular Pharmacology, 2010, 78(6): 1124-1134.

[62] Yang Shi-long, Xiao Yao, Kang Di, et al. Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models [J]. Proceedings of the National Academy of Sciences, 2013, 110(43): 17534-17539.

[63] Chun Yuen Chow, Ben Cristofori-Armstrong, Eivind A B Undheim, et al. Three peptide modulators of the human voltage-gated sodium channel 1.7, an important analgesic target, from the venom of an australian tarantula[J]. Toxins, 2015, 7(7): 2494-2513.

[64] Richard J Clark, Muharrem Akcan, Quentin Kaas, et al. Cyclization of conotoxins to improve their biopharmaceutical properties [J]. Toxicon, 2012, 59(4): 446-455.

[65] Undem B J, Carr M J. Targeting primary afferent nerves for novel antitussive therapy [J]. CHEST Journal, 2010, 137(1): 177-184.

[66] Ewan St John Smith, Damir Omerbaši?, Stefan G Lechner, et al. The molecular basis of acid insensitivity in the African naked mole-rat [J]. Science, 2011, 334(6062): 1557-1560.

Progress of Voltage Gated Sodium Channel Nav1.7 and its Specific Blockers in Nneuropathic pain

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles6

Recommended Articles

Metrics

[1]	JIAO Miao-miao, WANG Xu, ZHOU Na, ZHANG Meng, LIU Jin-na, TAN Zhan-wang, HUANG Dong-yang.Comparison of Analgesic Effects of Corydalis Yanhusuo，Radix Lindera，Jin Ling-zi powder and Xiao Huo-luo Dan on Rats with Neuropathic Pain#br#[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 1-.
[2]	ZHANG Fang-fang1，ZHOU Yan-memg1，WANG Hao1，GAO Shan1，WANG Lei1，TAN Rui1，DU Xian1，ZHAO Xiao-min1，ZHANG Han-ting1，2 *.PDE4 Inhibitor Ameliorates Neuropathic Pain by Upregulating Spinal Connexin 43 Expression[J]. Acta Neuropharmacologica, 2018, 8(4): 8-9.
[3]	WU Ya-ru，CHANG Ke-xin，JIA Qing-zhong.The Establishment and Evaluation of Animal Models of Neuropathic Pain[J]. Acta Neuropharmacologica, 2017, 7(5): 15-.
[4]	HONG Li-mian，JIN Gui-lin，CHU Mei-mei，YU Chang-xi.A Review on the Role of Microglia in Diabetic Neuropathic Pain[J]. Acta Neuropharmacologica, 2016, 6(3): 56-64.
[5]	LI Li，ZHANG Hai-lin.The Multi-target Mechanism of CCL2/CCR2 Involved in Neuropathic Pain[J]. Acta Neuropharmacologica, 2016, 6(1): 49-57.
[6]	YANG Ying, YU Long-Chuan.Changes of CGRP8-37-induced Antinociception and CGRP-immunoreactivity at Spinal Levels in Morphine Tolerant Rats[J]. Acta Neuropharmacologica, 2013, 3(2): 1-12.